Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2000-1-18
pubmed:abstractText
To evaluate the incidence of clinically relevant cardiac toxicity after treatment with epirubicin/paclitaxel-containing regimens in patients with metastatic breast cancer and to identify high-risk patients in whom the benefit of chemotherapy may be negated by the occurrence of congestive heart failure (CHF).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3596-602
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
pubmed:affiliation
Divisione di Oncologia Medica, Dipartimento di Oncologia, Ospedale Santa Chiara e Universita, Pisa, Italy. a.gennari@do.med.unipi.it
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't